Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 8/20 | 0.55 |
| ▸ | CCNB2 | O95067 | 7/20 | 0.55 |
| ▸ | CCNB1 | P14635 | 7/20 | 0.55 |
| ▸ | CCNB3 | Q8WWL7 | 7/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14472999 | 0.75 | AHCY (0.60) | ADORA2AADORA1 | |
| SCHEMBL10284145 | 0.75 | AHCY (0.60) | ADORA2AADORA1 | |
| SCHEMBL91112 | 0.75 | FDPS (0.48) | KMT2AADORA2AADORA1SMN1; SMN2 | |
| SCHEMBL2001785 | 0.73 | CDK1 (0.60) | CDK1CCNB2CCNB1CCNB3RAB9A | |
| SCHEMBL2006199 | 0.73 | TMIGD3 (0.60) | CDK1CCNB2CCNB1CCNB3RAB9A | |
| SCHEMBL8936762 | 0.72 | ADORA3 (0.55) | ADORA2AADORA1 | |
| SCHEMBL13248702 | 0.72 | ATM (0.43) | ADORA2A | |
| SCHEMBL14472889 | 0.72 | ATM (0.43) | ADORA2A | |
| SCHEMBL28068467 | 0.68 | TMIGD3 (0.77) | CDK1CCNB2CCNB1CCNB3RAB9A | |
| SCHEMBL14139510 | 0.68 | AHCY (0.56) | ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129357-B2 | N6-(4-hydroxybenzyl)adenosine; Gastrodia extract; neurodegenerative Huntington's disease; trinucleotide repeat disease; hypoglycemic; neurological antiinflammatory; amination of 6-chloropurine ribonucleoside with 4-hydroxybenzylamine; condensation of adenosine with 4-methoxybenzoyl chloride | ACADEMIA SINICA (TW) | 2012-03-06 | — | — | US | disclosed |
| US-20080176816-A1 | Method of making and using an adenosine analogue | ACADEMIA SINICA | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176816-A1 | Method of making and using an adenosine analogue | HTT, ADA, GDA | CDK1 3604/4885CCNB2 3577/4885CCNB1 3718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.